<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849952</url>
  </required_header>
  <id_info>
    <org_study_id>D12160</org_study_id>
    <nct_id>NCT01849952</nct_id>
  </id_info>
  <brief_title>Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas</brief_title>
  <official_title>Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes.
      Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas,
      known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b
      (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue.
      This study tests the hypothesis that in primary glioma samples mir-10b expression patterns
      will serve as a prognostic and diagnostic marker. This study will also characterize the
      phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the
      critical function of anti-mir-10b in blocking established glioblastoma growth, the
      investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b
      treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients
      diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b
      expression levels. Patient survival, as well as tumor grade and genotypic variations will be
      correlated to mir-10b expression levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Patients will be followed for survival every 12 weeks +/- 1 week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Astrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Oligoastrocytoma</condition>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Anaplastic Oligoastrocytoma</condition>
  <condition>Glioblastoma</condition>
  <condition>Brain Tumors</condition>
  <condition>Brain Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tumor tissue, cerebrospinal fluid.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in the clinic who are going to be treated with surgery, radiation and medical
        therapy for gliomas will be eligible for the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

          -  18 years of age

          -  Brain tumor(s) to be resected for clinical reasons.

          -  Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III
             or IV.

          -  Adequate tissue available for processing as determined by Pathology.

          -  Adequate decision making ability to review, discuss and sign a consent form to allow
             their tumor samples to be used for future human brain tumor biology laboratory
             research. Determination of capacity to consent is made by one of the co-investigators
             based on clinical assessment.

          -  Patients opting for the standard treatment regimen for their disease as well as
             ongoing clinical trials will be are eligible to participate in this study. Standard
             care for newly-diagnosed glioblastomas typically consists of surgical resection
             followed by radiotherapy with concomitant temozolomide, followed by adjuvant
             temozolomide chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arti B Gaur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Research Nurse</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Arti B Gaur, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilo E Fadul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.dartmouth.edu/pf/clinical_trial/D12160/</url>
    <description>Norris Cotton Cancer Center Clinical Trial Page</description>
  </link>
  <reference>
    <citation>Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007 Mar 15;67(6):2456-68.</citation>
    <PMID>17363563</PMID>
  </reference>
  <reference>
    <citation>Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol. 2011 Jun;13(6):580-90. doi: 10.1093/neuonc/nor033.</citation>
    <PMID>21636706</PMID>
  </reference>
  <reference>
    <citation>Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci. 2008 Oct;1142:108-32. doi: 10.1196/annals.1444.009. Review.</citation>
    <PMID>18990124</PMID>
  </reference>
  <reference>
    <citation>Lo HW. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol. 2010 Jan;3(1):37-52. Review.</citation>
    <PMID>20030624</PMID>
  </reference>
  <reference>
    <citation>Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009 Jun;19(3):188-97. doi: 10.1016/j.semcancer.2009.02.005. Epub 2009 Feb 20. Review.</citation>
    <PMID>19429483</PMID>
  </reference>
  <reference>
    <citation>Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials. 2010 Jan;5(1):14-27. Review.</citation>
    <PMID>20205684</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.</citation>
    <PMID>15758009</PMID>
  </reference>
  <reference>
    <citation>Salcman M. Survival in glioblastoma: historical perspective. Neurosurgery. 1980 Nov;7(5):435-9.</citation>
    <PMID>6255368</PMID>
  </reference>
  <reference>
    <citation>Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002 Mar 23;359(9311):1011-8. Review.</citation>
    <PMID>11937180</PMID>
  </reference>
  <reference>
    <citation>Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001 Feb;12(2):259-66.</citation>
    <PMID>11300335</PMID>
  </reference>
  <reference>
    <citation>Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88.</citation>
    <PMID>12672279</PMID>
  </reference>
  <reference>
    <citation>Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000 May;25(1):55-7.</citation>
    <PMID>10802656</PMID>
  </reference>
  <reference>
    <citation>Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001 Jul 1;61(13):4956-60.</citation>
    <PMID>11431323</PMID>
  </reference>
  <reference>
    <citation>Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007 Nov 1;21(21):2683-710. Review.</citation>
    <PMID>17974913</PMID>
  </reference>
  <reference>
    <citation>Dell'Albani P. Stem cell markers in gliomas. Neurochem Res. 2008 Dec;33(12):2407-15. doi: 10.1007/s11064-008-9723-8. Epub 2008 May 21. Review.</citation>
    <PMID>18493853</PMID>
  </reference>
  <reference>
    <citation>Standart N, Jackson RJ. MicroRNAs repress translation of m7Gppp-capped target mRNAs in vitro by inhibiting initiation and promoting deadenylation. Genes Dev. 2007 Aug 15;21(16):1975-82. Review.</citation>
    <PMID>17699746</PMID>
  </reference>
  <reference>
    <citation>de Moor CH, Meijer H, Lissenden S. Mechanisms of translational control by the 3' UTR in development and differentiation. Semin Cell Dev Biol. 2005 Feb;16(1):49-58. Epub 2005 Jan 12. Review.</citation>
    <PMID>15659339</PMID>
  </reference>
  <reference>
    <citation>Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol. 2007 Feb;210(2):279-89. Review.</citation>
    <PMID>17096367</PMID>
  </reference>
  <reference>
    <citation>Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005 Oct;15(5):563-8. Review.</citation>
    <PMID>16099643</PMID>
  </reference>
  <reference>
    <citation>Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006 Mar;17(3):189-202. Epub 2006 Mar 3. Review.</citation>
    <PMID>16518686</PMID>
  </reference>
  <reference>
    <citation>Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97-109. Epub 2007 Jul 6. Review. Erratum in: Acta Neuropathol. 2007 Nov;114(5):547.</citation>
    <PMID>17618441</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>miRNA</keyword>
  <keyword>GBM</keyword>
  <keyword>astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

